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Abstract
Background: The complications of hypertension cause severe health problems in rural areas in China. We (i)
screened the major factors inducing hypertensive complications and provided intervention measures; and (ii)
verified the efficacy of the New Rural Cooperative Medical Scheme (NRCMS; a medical insurance scheme for rural
residents) for hypertension management.
Methods: A survey was conducted in the villages of Yunnan (an underdeveloped province in southwest China).
The NRCMS was initiated there in 2005. Data were collected through questionnaires, physical examination,
electrocardiography, as well as blood and urine tests. To detect factors inducing hypertension complications, a
generalized estimating equations model was developed. Multivariable logistic regression was used to analyze
influencing factors for hypertension control.
Results: Poor management of hypertension was observed in women. Being female, old, poorly educated, a
smoker, ignorant of the dangerousness of hypertension, and having uncontrolled hypertension made patients
more prone to hypertension complications. Combination therapy with ≥2 drugs helped control hypertension, but
most rural patients disliked multidrug therapy because they considered it to be expensive and inconvenient. The
NRCMS contributed little to reduce the prevalence of complications and improve control of hypertension.
Conclusions: The present study suggested that the NRCMS needs to be reformed to concentrate on early
intervention in hypertension and to concentrate on women. To increase hypertension control in rural areas in
China, compound products containing effective and inexpensive drugs (and not multidrug therapy) are needed.
Keywords: hypertension complications, Chinese rural areas, the New Rural Cooperative Medical Scheme
Background
Hypertension is one of the leading causes of cardiovascu-
lar disease and premature mortality in the world [1].
Uncontrolled hypertension results in various complica-
tions (e.g., coronary heart disease, stroke, congestive
heart failure, renal insufficiency, and peripheral vascular
disease [2]), which are the major causes of morbidity and
mortality. In China, hypertension is a common health
problem with a rising prevalence. From 1960 to 2002, the
number of hypertensive patients among Chinese adults
rose from 30 million to 129 million [3,4]. However, the
awareness, treatment, and control of hypertension are
relatively poor. Among hypertensive patients in China,
44.7% are aware that they have high blood pressure,
28.2% are taking antihypertensive medications, and 8.1%
achieve control of blood pressure [3]. The rates of aware-
ness, treatment, and control are even lower in rural areas
in China, although the prevalence of hypertension in
rural areas is similar to that in urban areas [5]. China has
744.71 million people involved in agriculture, which is
57.01% of the total population of China [6]. The largest
number of hypertensive patients is in rural areas.
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sion in the countryside bring about serious complications
which have become a heavy burden on the health system
in China. Strengthening medical monitoring in rural
areas and taking steps to reduce complications due to
uncontrolled hypertension should be priorities for Chi-
nese health authorities.
For rural residents not employed in formal employ-
ment, the Chinese government has been rolling out a
medical insurance scheme called the “New Rural Coop-
erative Medical Scheme” (NRCMS) since 2003. It is a
voluntary health insurance program funded by enrollee
contributions and by subsidies from central and local
governments. Households purchase health insurance for
modest premiums of 10-20 Yuan RMB (~$1.50-3.00) per
person per annum; local and central governments each
contribute 20-40 Yuan RMB per enrolled individual [7].
The NRCMS is administered at the county level, so cov-
erage has varied across regions of China and over time.
County administrators define benefits packages on the
basis of local needs and resources [8]. By 2005, the
NRCMS in all pilot counties covered inpatient care; how-
ever, only one-quarter included outpatient expenses on a
pooling basis. The bulk of reimbursement by the
NRCMS was for inpatient expenses, even in counties that
covered outpatient expenses [7]. To supplement the
NRCMS, Medical Financial Assistance (MFA) was estab-
lished in 2003. MFA is supposed to provide assistance
mainly for the designated poor (who are identified by
local governments according to the national extreme and
relative poverty lines) to pay the NRCMS premium and
part of the NRCMS non-reimbursable medical expenses
[9]. Other medical insurance programs (e.g., private
insurance) are rarely purchased by rural residents. The
NRCMS is the largest health insurance program in Chi-
nese rural areas. By 2010, the average coverage of the
NRCMS throughout China has been ≥95%. This program
is expected to reduce the financial burden on rural resi-
dents and improve their health status, but its effective-
ness needs to be confirmed.
T h ea i mo ft h ep r e s e n ts t u d yw a st os c r e e nt h em a j o r
factors inducing hypertensive complications among rural
residents. Also, the effectiveness of the NRCMS for
increasing control of hypertension and decreasing the pre-
valence of complications was evaluated to provide inter-
vention measures to improve hypertension control and
prevent complications in patients living in rural areas. The
study was done in the mountainous areas of Yunnan pro-
vince (an under-developed area in southwest China).
Methods
The study protocol was approved by the Ethics Com-
mittee of Kunming Medical University (Yunnan, China).
Each participant provided written informed consent.
Study subjects
We identified four mountain villages in Binchuan
County (an agricultural county with a low economic
level in the west of Yunnan province) as the study sites.
It joined the NRCMS in 2005, but was not the pilot
county of MFA at the time of the survey. An investiga-
tion was made from February to April in 2007 (a short
period before spring ploughing to ensure the maximum
number of young adults stayed in their native villages
instead of going out to work). There were 2,022 house-
holds, with 7,665 people in these villages. All villagers
were peasants, and 71.2% of them were covered by the
NRCMS. The household survey was conducted for all
villagers aged ≥25 years.
Measurement of blood pressure (BP)
The BP of participants was taken in their homes by
trained technicians. BP was measured in the right arm
supported at the heart level with a standardized mercury
sphygmomanometer after a rest of ≥5 min. BP was mea-
sured twice with 30 s of rest between each measure-
ment. The mean of two readings was used for analyses.
Hypertension was defined as systolic blood pressure
(SBP) ≥140 mmHg, and/or diastolic blood pressure
(DBP) ≥90 mmHg, and/or reported treatment with anti-
hypertensive agents in the past 2 weeks. The prevalence
of awareness was defined as the percentage of hyperten-
sive subjects reporting a prior diagnosis of hypertension.
The prevalence of treatment was defined as the percen-
tage of hypertensive patients with a history of therapy
using antihypertensive drugs. The prevalence of control
was defined as the percentage of hypertensive patients
with BP controlled <140/90 mmHg.
Collection of demographic and laboratory data
Demographic data were obtained from in-house surveys.
Research staff administered a questionnaire to collect
personal data (age, sex, height, weight, medical history,
number of years of schooling, smoking status, alcohol
consumption, household income, disposable income), as
well as finding out if the participant had joined the
NRCMS or other insurance schemes. For those consid-
ered to have hypertension, questions with regard to the
awareness of high BP, knowledge of the dangerousness of
hypertension, and treatment status were asked. Questions
about medicine names, treatment cost, and the maxi-
mum acceptable cost of treatment per month were
inquired among patients who received antihypertensive
treatment.
Once subjects were defined as having hypertension, they
were invited to village clinics to undergo electrocardiogra-
phy (ECG) and to donate samples of blood and urine. A
routine urine test was conducted and the level of creati-
nine in serum determined in the clinical laboratory of the
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on the same day as sample collection. Electrocardiograms
were delivered to the First Affiliated Hospital of Kunming
Medical University (Kunming, P. R. China) to be analyzed
by technicians unconnected to the study.
Detecting the adverse outcomes of hypertension
For subjects with hypertension, the adverse outcomes of
this disorder were detected. In the present study, out-
comes were classified as “brain damage”, “heart
damage”, “kidney damage”,a n d“other”. Hypertensive
patients with histories of stroke and/or transient
ischemic attack were placed in the “brain damage” cate-
gory. Heart damage was ascertained as having any of the
following: (1) ECG showing left-ventricular hypertrophy:
Sokolow-Lyon index >38 mm or Cornell voltage product
>2440 mm·ms [10]; (2) signs and symptoms of heart
failure presented by excluding other causes through
questions regarding medical history; and (3) patients
with the typical chest pain associated with angina pec-
toris. Patients in whom routine urinalysis showed urine
protein to be positive, and/or serum creatinine >1.5 mg/
dL, were classified as having kidney damage. Other out-
comes due to hypertension such as fundus bleeding
and/or intermittent claudication were classified to the
“other” category.
Statistical analyses
Statistical analyses were undertaken using the Stata 10
statistical package. Continuous variables are presented
as means and discrete variables as frequencies and per-
centages. The Student’s t-test and one-way analysis of
variance for continuous variables, and the chi-square
test for categorical factors, were applied to compare
across the groups. Next, to estimate the occurrence of
hypertensive adverse consequences based on potential
risk factors, a model was developed via generalized esti-
mating equations (GEE). In this model, hypertension
outcome was adopted as the dependent variable, and
potential risk factors as independent variables. Hyper-
tension outcomes were divided into four categories, and
one hypertensive patient could experience one or more
outcomes simultaneously. These were multiple response
data in which different options in the multiple response
data were not only interconnected, but also relatively
independent. The data can be analyzed by building the
model of GEE [11]. Subsequently, another model was
developed to analyze the influence of factors on the
control prevalence of hypertension among patients who
received antihypertensive treatment. Multivariable step-
wise logistic regression was used on this occasion. A
two-sided P value of <0.05 was considered to be
significant.
Results
Among 7,665 villagers, 5,682 individuals were ≥25 years.
Except those who were away from home or unwilling to
be interviewed, 5,110 individuals were enrolled in this
survey. Male subjects accounted for 51.9% (2652/5110).
The prevalence of NRCMS coverage among all subjects
was 70% (3577/5110). No participant purchased private
medical insurance at the time of this survey.
Prevalence, awareness, treatment, and control of
hypertension
High BP or hypertensive history was detected in 1,340
subjects (714 males and 626 females). The prevalence of
hypertension in all subjects was 26.2% (26.9% in males
and 25.5% in females). There was no significant differ-
ence in the prevalence of hypertension between sexes
(p = 0.237). Among all subjects defined as having hyper-
tension, 436 subjects were aware of their high BP, 351
subjects were taking antihypertensive medicines, and 93
patients had their BP under control. The prevalence of
awareness, treatment and control of hypertension was
32.4%, 26.2%, and 6.9% respectively.
Data in different groups
The hypertensive group and normotensive group showed
no significant difference in sex ratio, prevalence of
NRCMS coverage, daily intake of alcohol, family income
per month, and personal disposable income per month
(p > 0.05). Subjects with hypertension were older and
had a higher body mass index (BMI) than those without
hypertension (p < 0.05). Smoking and lack of education
were more common in the hypertensive group (p < 0.05).
The data of male and female hypertensive patients are
presented at Table 1. Female patients had a lower preva-
lence of medical-insurance coverage, higher occurrences
of hypertensive outcomes, shorter duration in school, less
disposable income, less treatment costs, and less maxi-
mum acceptable treatment cost. Family income was simi-
lar in the two groups. Compared with male patients,
more female understood the danger of hypertension, but
the prevalence of awareness, treatment and control of
hypertension were lower in female patients.
Antihypertensive agents used among hypertensive
patients
Among patients receiving antihypertensive treatment,
the commonest agents are the compound drugs listed
below.
￿ Compound tablet of kendir leaves: each tablet con-
tains guanethidine (1.3 mg), hydralazine (1.6 mg),
hydrochlorothiazide (1.6 mg), and kendir leaves
(218.5 mg).
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santhemi flos: each tablet contains clonidine (0.03
mg), hydrochlorothiazide (5 mg), Chrysanthemi flos
powder (10 mg), pearl powder (100 mg), and melin
(20 mg).
￿ Compound antihypertensive tablet: each tablet
contains reserpine (0.03125 mg), potassium chloride
(30 mg), hydrochlorothiazide (3.125 mg), and hydra-
lazine (3.125 mg).
￿ Compound tablet of dihydralazine sulfate and
hydrochlorothiazide: each tablet contains dihydrala-
zine (5 mg), clonidine (0.015 mg), and hydrochlor-
othiazide (5 mg).
Figure 1 details the antihypertensive therapeutic pro-
tocols. A total of 44.0% of patients took one type of the
compound drugs described above. The remaining anti-
hypertensive agents were calcium-channel blockers
(35.3%), inhibitors of the renin-angiotensin system
(17.2%), diuretics (14.4%), and b-receptor antagonists
(8.0%). Patients administered compound products were
no longer treated with other antihypertensive drugs.
According to their therapeutic protocols, patients who
received drug therapy were divided into three groups.
These were the compound drugs group (taking one of
compound products mentioned above, 44%), single drug
group (taking other single drugs, 34%), and multidrug
therapy group (treated with ≥2d r u g s ,2 2 % ) .O ft h e s e
patients, 78% were treated with one single drug. Treat-
ment with a single drug rather than multiple drugs was
regarded as the most inexpensive and convenient by
most subjects. The number of medications used was
similar between males and females. The total treatment
cost among patients receiving antihypertensive treat-
ment was 3141 Yuan RMB per month, and the propor-
tion of reimbursement by the NRCMS was 2.5%.
Among single-drug, compound-drugs and multidrug
therapy groups, the treatment cost per month showed a
significant difference (5.85 vs. 13.49 vs. 15.35, respec-
tively), but there was no significant difference between
the compound drugs group and multidrug group (p =
0.118).
GEE Model
Before developing the GEE model, a high correlation was
found in three variables which reflected the economic
status of subjects: family income per month, personal dis-
posable income per month, and maximum acceptable
treatment cost per month (r = 0.72-0.91, p < 0.01). To
Table 1 Data of hypertensive patients in male and female groups
Male Female P
Number 714 626
Age (y) 65.5 ± 9.1 67.2 ± 8.7 0.0008
BMI (kg/m
2) 29.7 ± 6.1 22.6 ± 3.3 <0.0001
Smokers (%) 95.0(678/714) 59.6(373/626) <0.0001
Daily intake of alcohol (mL) 50.2 ± 6.5 28.8 ± 8.2 <0.0001
Number of years of schooling (y) 3.3 ± 2.7 1.3 ± 1.4 <0.0001
Insurance coverage (%) 73.1 66.3 0.007
Family income per month (Yuan RMB*) 684.6 ± 173.9 673.1 ± 149.5 0.1979
Personal disposable income per month (Yuan RMB*) 456.9 ± 188.9 292.2 ± 104.3 <0.0001
Monthly treatment cost (Yuan RMB*) 10.9 ± 9.6 5.9 ± 5.3 <0.0001
Maximum acceptable treatment cost per month (Yuan RMB*) 126.1 ± 83.8 65.1 ± 33.7 <0.0001
Understanding of the danger of hypertension (%) 12.9(92/714) 16.8(105/626) 0.045
Awareness (%) 36.0(257/714) 28.6(179/626) 0.004
Treatment (%) 30.1(215/714) 21.7(136/626) <0.0001
Control (%) 9.1(65/714) 4.6(29/626) 0.001
Hypertension outcomes (%) 41.7(298/714) 48.4(303/626) 0.014
*Currency = Renminbi, currency unit = Yuan, US$1.00 = RMB 6.844
BMI: Body mass index.
Figure 1 Antihypertensive therapeutic scheme among
hypertensive patients undergoing treatment. CCB: calcium
channel blockers. RASI: rennin-angiotensin system inhibitors. BRA:
beta receptor antagonists.
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principal components analysis (PCA) was adopted. Three
principal components were extracted based on PCA. The
variance contribution of the first principal component
had reached 86.5% (which was sufficient to mirror the
information of the original three variables), so the first
principal component was named “personal economic
condition” to go to the next analysis. The expression was:
Personal economic condition = −4.36645 + 0.003357 × family income per month + 0.003397 × personal
disposable income per month + 0.008151 × maximum acceptable treatment cost per month
A GEE model was fitted (Table 2). Four constants
were fitted into this model to reflect the natural loga-
rithm of the odds ratio (OR) of the prevalence of four
hypertension outcomes on the baseline. Adjusted by all
variables, the prevalence of hypertensive outcomes was
0.69‰ (brain damage), 0.13‰ (heart damage), 0.26‰
(kidney damage), and 0.02‰ (other). The results of the
GEE model showed that being female, old, smoking
tobacco products, and having awareness of hypertension
were the promoting factors to adverse outcomes of
hypertension (p < 0.001, respectively). Conversely, a
longer duration of schooling (p = 0.014), better personal
economic condition (p < 0.001), understanding the dan-
ger posed by hypertension (p = 0.002), and well-con-
trolled BP (p < 0.001) were inhibitory factors for
hypertension outcomes. Having medical insurance (p =
0.925) and receiving hypertensive treatment (p = 0.782)
did not contribute to the prevention of the adverse out-
comes of hypertension.
Logistic regression model
The results of stepwise logistic analysis are shown in
Table 3. Combination therapy with ≥2d r u g s ,u n d e r -
standing the danger due to hypertension, compound
drugs therapy, and higher treatment cost were beneficial
to hypertension control. Conversely, being female and
smoking ≥20 cigarettes per day were not beneficial to
hypertensive control. Joining the NRCMS and receiving
Table 2 Results of generalized estimating equations
Coefficient Standard error z P
Cons_1 -7.27491 0.8533082 -8.53 0
Cons_2 -8.921791 0.8670381 -10.29 0
Cons_3 -8.253619 0.8607792 -9.59 0
Cons_4 -10.71109 0.8952318 -11.96 0
Female (vs. male) 1.389162 0.1959131 7.09 0
Age 0.0532048 0.0079643 6.68 0
BMI -0.114449 0.009973 -1.15 0.251
Joining NRCMS (vs. not joining) -0.009856 0.1041018 -0.09 0.925
Daily smoking (vs. not smoking)
<10 cigarettes 0.6989892 0.1490481 4.69 0
10-20 cigarettes 1.880096 0.1982579 9.48 0
21-30 cigarettes 4.164752 0.2797552 14.89 0
31-40 cigarettes 5.027749 0.3877939 12.97 0
>40 cigarettes 5.423671 0.4484097 12.1 0
Daily alcohol intake (vs. not drinking)
<50 mL -0.144686 0.1352986 -1.07 0.285
50-100 mL 0.0492849 0.1462375 0.34 0.736
>100-150 mL 0.2496853 0.371617 0.67 0.502
>150-200 mL 0.9168573 0.4639914 1.98 0.048
>200 mL 0.1791324 0.870807 0.21 0.837
Number of years of schooling -0.077254 0.0313048 -2.47 0.014
Financial capacity -0.213526 0.0570027 -3.75 0
Awareness of hypertension 1.545984 0.1657462 9.33 0
Understanding the danger due to hypertension -0.585789 0.1877989 -3.12 0.002
Treatment of hypertension -0.052023 0.1910931 -0.27 0.785
Control of hypertension -1.67305 0.3589172 -4.66 0
_1 Brain damage
_2 Heart damage
_3 Kidney damage
_4 Other
NRCMS: New Rural Cooperative Medical Scheme, BMI: body mass index
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model.
Discussion
Hypertension is a common health problem in ‘develop-
ing’ countries [12]. We revealed an overall prevalence of
hypertension of 26.2% in Yunnan province. The preva-
lence of hypertension was 26.9% in men and 25.5% in
women. The general prevalence of awareness, treatment
and control were lower than that observed in adults in
the USA [13] and the mean level of Chinese adults [3].
That is, hypertension is a serious health problem in
rural areas of China.
The World Bank in 2009 [14] reported that the num-
ber of people living in poverty in China in 2005 was 254
million, and that the poor were predominantly from
rural areas. The prevalence of hypertension was similar
in rural and urban areas, but treatment and control in
rural areas was not good [5]; this was largely due to the
cost of obtaining medical treatment [7]. The medical
insurance program provided by the Chinese government
is particularly needed by farmers.
The NRCMS focuses largely on the costs of inpatient
care rather than the costs of basic services (including per-
sonal and communal preventive interventions); also,
reimbursement of outpatient expenses can be difficult to
obtain. A recent study [15] showed that the NRCMS
could not protect against financial catastrophe and
household impoverishment. For most chronic diseases
such as hypertension, inpatient care is at a late stage of
medical intervention, which is expensive. Early interven-
tions (including preventive care and outpatient care) are
more cost-effective than inpatient care. We showed that
smoking, lacking knowledge of the dangerousness of
hypertension, and having uncontrolled hypertension
made hypertensive subjects prone to various complica-
tions. Most patients seldom realized their high BP status
until complications occurred( w h i c hc o u l de x p l a i nw h y
awareness of hypertension became a promotion factor to
induce hypertensive complications). Education regarding
smoking cessation, improving people’s understanding of
hypertension, and regular follow-up in clinics are cost-
effective methods to increase hypertension control and
decrease its complications.H o w e v e r ,t h ec o s t so ft h e s e
methods are neglected by the NRCMS. This could be
why the NRCMS does not help to improve hypertension
management. Another study revealed [16] that adding
outpatient reimbursement to the benefit package encour-
aged poor families to use healthcare services and thus
reduced their potential need for hospitalization and its
financial burden.
Prevalence of the awareness of hypertension and treat-
ment in women is higher than that in men [3,5,13,17-20],
and good control of BP in women more readily obtained.
However, the present study showed poorer management
of hypertension in women. Female patients had a lower
degree of education as well as less medical-insurance
coverage. Even if their family income was similar to that
of men, women had less disposable income, treatment
costs, and maximum acceptable treatment cost. This mir-
rored the second-class status that women have within the
family and society in China. Should be the NRCMS
change so that it helps rural women? Should a special
fund be established for the healthcare of rural women?
Could new medical reforms resolve these problems?
Answers to all of these questions are needed.
Multiple studies have shown that good control of BP is
vital to avoiding dangerous complications [21-23]. How-
ever, a low prevalence of adequate control of BP has been
documented in the USA, Spain, Canada, France and the
UK [24-29], and this situation was reflected in the pre-
sent study. Antihypertensive treatment could not prevent
the complications of hypertension unless good control of
BP was obtained, and combination therapy with ≥2 drugs
was conducive to achieve optimal control of BP. This is
consistent with the recommendations of JNC 7 [30].
More than 75% of patients preferred single-drug therapy,
and only 22% of patients underwent multidrug combina-
tion therapy. Compound drugs were well received by
Chinese farmers (44%). These compound drugs usually
contain traditional Chinese medicines and Western med-
icines at a low dose (e.g., hydrochlorothiazide, hydrala-
zine, reserpine). They are called “traditional compound
drugs” (TCDs), have been used to reduce BP in China
since the 1950s, and are widely accepted by Chinese peo-
ple (especially farmers) due to their low cost and
Table 3 Results of logistic regression analysis
Coefficient Odds ratio z P
Constants -7.952181 -6.32 0
Multidrug therapy 3.763052 43.07971 5.49 0
Understanding of the danger of hypertension 4.118705 61.47958 7.2 0
Female -1.529124 0.2167254 -3.39 0.001
Traditional compound drugs therapy 1.404991 4.075489 2.65 0.008
Treatment cost 0.0824604 1.085956 2.63 0.009
More than 20 cigarettes per day -2.182919 0.112712 -2.32 0.02
Zhang et al. BMC Public Health 2011, 11:301
http://www.biomedcentral.com/1471-2458/11/301
Page 6 of 8convenience. We revealed TCDs to be beneficial to good
control of BP but their effects for lowering BP and pro-
tecting target organs (or their side effects) have not been
confirmed by large clinical trials. The efficacy and toler-
ability of some compound antihypertensive drugs (e.g.,
losartan/hydrochlorothiazide, amlodipine/valsartan, irbe-
sartan/hydrochlorothiazide, perindopril/indapamide)
have been confirmed by evidence-based studies [31-34].
These compound products are low fixed-dose combina-
tions of two antihypertensive drugs and are called “mod-
ern compound drugs” (MCDs). The cost of MCDs
interferes with their application in Chinese rural areas
despite their high efficacy and excellent tolerability. The
monthly treatment cost of each MCD described above is
>200 Yuan RMB. According to the maximum acceptable
treatment cost of subjects in the present study, only 5.5%
could bear the cost; >94% could not afford it.
Our survey suggested that some multidrug combina-
tion therapy protocols, such as combination therapy
with nitrendipine and captopril (or enalapril), nitrendi-
pine and metoprolol, or hydrochlorothiazide and capto-
pril, were effective and sufficiently inexpensive to be
afforded by most rural patients. However, multidrug
therapy was considered to be expensive and inconveni-
ent, and seldom accepted by most patients. If these
inexpensive and efficacious drugs were made into com-
pound products (e.g., nitrendipine + captopril, or nitren-
dipine + metoprolol) they could be readily accepted by
most Chinese farmers. These compound drugs could
improve the control of hypertension, and should be
tried by Chinese health authorities.
This study had limitations. First, we did not exclude
white-coat hypertension and secondary hypertension
from hypertensive subjects. Second, among hypertensive
subjects, adverse outcomes were probably missed due to
incomplete tests. For the sake of excluding white-coat
hypertension or secondary hypertension, some medical
checks (e.g., ambulatory blood pressure monitoring, aor-
tic MRI, adrenal CT) should be undertaken. Similarly,
more target-organ damage could be detected if echocar-
diography, CT or MRI of the head, or the microalbumin
urine test was carried out. However, this was an epide-
miological study involving thousands of people. It is
unrealistic to undertake such expensive investigations.
Finally, organ damage (heart, brain, kidney) could have
resulted from other illnesses (e.g., diabetes). However, it
is quite common for hypertensive patients to also have
diabetes. Among 1,340 hypertensive subjects detected,
128 subjects were urine glucose-positive and/or had a
history of diabetes. The prevalence of diabetes among
hypertensive subjects was 9.6%. Hypertension and dia-
betes interact, coordinate and contribute to target-organ
damage. The individuals with diabetes could not be
eliminated from hypertensive subjects in case the rest of
the subjects were not representative of the total hyper-
tensive population.
Conclusions
Early intervention, such as health education and regular
follow-up in clinic, can decrease the complications of
hypertension. However, the cost of early intervention is
ignored by the NRCMS. The present study showed
poorer management of hypertension in rural women,
and showed that the NRCMS contributes little to hyper-
tension management. We suggest that the NRCMS
should concentrate on early intervention of hypertension
and to focus on women. To increase hypertension con-
trol in rural areas in China, compound products con-
taining effective and inexpensive drugs (and not
multidrug therapy) are needed.
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